PARIS--(BUSINESS WIRE)--Regulatory News:
Cellnovo Group (“Cellnovo”, CLNV:EN Paris) (Paris:CLNV), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, today announces a system upgrade which will allow patients using CGM (Continuous Glucose Monitoring) to input their glucose levels manually. This enhanced capability has been introduced to provide greater comfort, convenience and flexibility for the growing number of type 1 diabetes patients using CGM devices.
CGM devices enable patients to measure their glucose levels without the need for finger pricks. The upgrade to the Cellnovo system now enables patients using CGM devices to manually input their level readings directly into the Cellnovo handset. The system’s on board bolus calculator will then derive the required insulin dose.
Cellnovo intends to complement the CGM feature before the end of the year by launching a mobile monitoring app that will display continuous CGM profiles and insulin delivery patterns for Cellnovo users.
Sophie Baratte, CEO of Cellnovo, commented: “CGM technology is becoming increasingly popular amongst type 1 diabetes patients as an alternative to traditional Blood Glucose Monitoring. The addition of this innovative feature to our system demonstrates our ability to identify and adapt to the latest user needs and technology improvements. We believe that providing more comfort and flexibility for CGM users will further increase the appeal of our diabetes management system which already offers patients a number of outstanding features including an ultra compact design combined with high levels of accuracy.”
------
About Cellnovo
An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first mobile, connected all-in-one diabetes management system that helps make life easier for patients. Compact, tubeless, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real-time.
For further information please visit www.cellnovo.com
About the Cellnovo Diabetes Management System
Compact, tubeless, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections with drop-by-drop precision, whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real-time.
Cellnovo is listed on Euronext, Compartment C
ISIN: FR0012633360 –
Ticker: CLNV